An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: A randomized, double-blind, placebo-controlled trial with tocolytic rescue

American Journal of Obstetrics and Gynecology

Volumn 182, Issue 5, 2000, Pages 1173-1183

  Romero, Roberto ^{a,b,c,d,e,f,g,h,i,j}   Sibai, Baha M ^{a,b,c,d,e,f,g,h,i,j}   Sanchez Ramos, Luis ^{a,b,c,d,e,f,g,h,i,j}   Valenzuela, Guillermo J ^{a,b,c,d,e,f,g,h,i,j}   Veille, Jean Claude ^{a,b,c,d,e,f,g,h,i,j}   Tabor, Bannie ^{a,b,c,d,e,f,g,h,i,j}   Perry, Kenneth G ^{a,b,c,d,e,f,g,h,i,j}   Varner, Michael ^{a,b,c,d,e,f,g,h,i,j}   Goodwin, T Murphy ^{a,b,c,d,e,f,g,h,i,j}   Lane, Rosanne ^{a,b,c,d,e,f,g,h,i,j}   Smith, Judith ^{a,b,c,d,e,f,g,h,i,j}   Shangold, Gary ^{a,b,c,d,e,f,g,h,i,j}   Creasy, George W ^{a,b,c,d,e,f,g,h,i,j}  

^a HUTZEL HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF FLORIDA HEALTH SCIENCE CENTER   (United States)

^d San Bernardino County Medical Center   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f WAKE FOREST UNIVERSITY   (United States)

^g JOHN PETER SMITH HOSPITAL   (United States)

^h UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF UTAH   (United States)

^j R W JOHNSON PHARMACEUTICAL RES I   (United States)

more..

Author keywords

Atosiban; Oxytocin; Oxytocin receptor antagonist; Prematurity; Preterm labor; Randomized clinical trial; Tocolysis

Indexed keywords

ANTOCIN; ATOSIBAN; OXYTOCIN ANTAGONIST; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FETUS DEATH; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; NEWBORN DEATH; PREMATURE LABOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOCOLYSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0034096854     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2000.95834     Document Type: Article

References (44)

1. 1. Report of the Consensus Development Conference on the effect of corticosteroids for fetal maturation on perinatal outcomes. Washington: National Institutes of Health; 1994 Nov. NIH Publication No.: 95-3784.
2. 2. Brown ER, Epstein MF. Neonatal consequences of preterm birth. In: Fuchs A-R, Fuchs F, Stubblefield PG, editors. Preterm birth: causes, prevention, and management. 2nd ed. New York: McGraw-Hill; 1993. p. 465-75.
3. 3. Escobedo MB. Follow-up of prematurely born infants. Clin Obstet Gynecol 1988;31:662-70.
4. 4. Arias F, Tomich P. Etiology and outcome of low birth weight and preterm infants. Obstet Gynecol 1982;60:277-81.
5. 5. King JF, Grant A, Keirse MJN. Betamimetics in preterm labour: an overview of the randomized controlled trials. Br J Obstet Gynaecol 1988;95:211-22.
6. 6. The Canadian Preterm Labor Investigators Group. Treatment of preterm labor with the beta-adrenergic agonist ritodrine. N Engl J Med 1992;327:308-12.
7. 7. Merkatz IR, Peter JB, Borden TP. Ritodrine hydrochloride: a beta-mimetic agent for use in preterm labor. II. Evidence of efficacy. Obstet Gynecol 1980;56:712.
8. 8. Hudgens DR, Conradi SE. Sudden death associated with terbutaline sulfate administration. Am J Obstet Gynecol 1993;169: 120-1.
9. 9. Katz M, Robertson PA, Creasy RK. Cardiovascular complications associated with terbutaline treatment for preterm labor. Am J Obstet Gynecol 1981;139:605-8.
10. 10. Foley MR, Landon MB, Gabbe SG, O'Dorisio TM, Waxman M, Leard R, et al. Effect of prolonged oral terbutaline therapy on glucose tolerance in pregnancy. Am J Obstet Gynecol 1993; 168:100-5.
11. 11. Macones G, Sehdev H, Berlin M, Morgan M, Berlin J. Efficacy of oral beta-agonist maintenance therapy in preterm labor: a meta-analysis. Obstet Gynecol 1995;85:313-7.
12. 12. Besinger RE, Niebyl JR, Keyes WG, Johnson TR. Randomized comparative trial of indomethacin and ritodrine for the long-term treatment of preterm labor. Am J Obstet Gynecol 1991;164:981-8.
13. 13. Molnar M, Hertelendy F. Regulation of intracellular free calcium in human myometrial cells by prostaglandin F2 alpha: comparison with oxytocin. J Clin Endocrinol Metab 1990;71: 1243-50.
14. 14. Norton ME, Merrill J, Cooper BAB, Kuller JA, Clyman RI. Neonatal complications after the administration of indomethacin for preterm labor. N Engl J Med 1993;329:1602-7.
15. 15. Zingg H, Lefebvre D, Giaid A. Uterine oxytocin gene expression: a novel framework for oxytocin action. Regul Pept 1993;45:43-6.
16. 16. Fuchs AR, Romero R, Deefe D, Parra M, Oyarzun E, Behnke E. Oxytocin secretion and human parturition: pulse frequency and duration increase during spontaneous labor in women. Am J Obstet Gynecol 1991;165:1515-23.
17. 17. Fuchs AR, Fuchs F, Husslein P, Soloff MS. Oxytocin receptors in the human uterus during pregnancy and parturition. Am J Obstet Gynecol 1984;150:734-41.
18. 18. Soloff M, Fuchs AR, Fuchs F. Oxytocin receptors and the onset of parturition. In: Albrecht E, Pepe G, editors. Perinatal endocrinology. Baltimore (MD): Perinatology Press; 1985. p. 289-311.
19. 19. Akerlund M, Stromberg P, Hauksson A, Andersen LF, Lyndrup J, Trojnar J, et al. Inhibition of uterine contractions of premature labour with an oxytocin analogue: results from a pilot study. Br J Obstet Gynaecol 1987;94:1040-4.
20. 20. Giussani DA, Jenkins SL, Mecenas CA, Winter JA, Barbera M, Honnebier OM, et al. The oxytocin antagonist atosiban prevents androstenedione-induced myometrial contractions in the chronically instrumented, pregnant rhesus monkey. Endocrinology 1996;137:3302-7.
21. 21. Goodwin TM, Paul R, Silver H, Spellacy W, Parsons M, Chez R, et al. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human. Am J Obstet Gynecol 1994; 170:474-8.
22. 22. Goodwin TM, Millar L, North L, Abrams L, Weglein R, Holland M. The pharmacokinetics of the oxytocin antagonist atosiban in pregnant women with preterm uterine contractions. Am J Obstet Gynecol 1995;173:913-7.
23. 23. Goodwin TM, Valenzuela G, Silver H, Creasy G, the Atosiban Study Group. Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor. Obstet Gynecol 1996;88:331-61.
24. 24. Phaneuf S, Asboth G, MacKenzie IZ, Melin P, Lopez Bernal A. Effect of oxytocin antagonists on the activation of human myometrium in vitro: atosiban prevents oxytocin-induced desensitization. Am J Obstet Gynecol 1994;171:1627-34.
25. 25. Schoenfeld D. The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika 1981;68:316-9.
26. 26. Gillings D, Koch G. The application of the principle of intention-to-treat to the analysis of clinicial trials. Drug Inform J 1991;25:411-24.
27. 27. Lee ET. Statistical methods for survival data analysis. 2nd ed. New York: John Wiley; 1992. p. 1-4.
28. 28. WHOART version 1992, third quarter. WHO, The Uppsala Monitoring Center, WHO Collaborating Centre for International Drug Monitoring, Stora Torget 3, S-753 20 Uppsala, Sweden.
29. 29. Goldenberg RL, Rouse DJ. Prevention of premature birth. N Engl J Med 1998;339:313-20.
30. 30. Keirse MNJC, Grant A, King JF. Preterm labour. In: Chalmers I, Enkin MW, Keirse MJNC, editors. Volume 1: effective care in pregnancy and childbirth. Oxford (United Kingdom): Oxford University Press; 1989. p. 194-202.
31. 31. Romero R, Mazor M, Munoz H, Gomez R, Galasso M, Sherer DM. The pretem labor syndrome. Ann N Y Acad Sci 1994;734:414-29.
32. 32. Romero R, Sirtori M, Ovarzun E, Avila C, Mazor M, Callahan R, et al. Infection and labor. V. Prevalence, microbiology, and clinical significance of intraamniotic infection in women with preterm labor and intact membranes. Am J Obstet Gynecol 1989;161:817-24.
33. 33. Gomez R, Romero R, Ghezzi F, Yoon BH, Mazor M, Berry SM. The fetal inflammatory response syndrome. Am J Obstet Gynecol. 1998;179:194-202.
34. 34. Gore E. Perinatal fluid and electrolyte regulation: role of arginine vasopressin. Semin Perinatol 1989;12:134-42.
35. 35. Advisory Committee for Reproductive Health Drugs. Bethesda (MD): Center for Drug Evaluation and Research, Food and Drug Administration; 1998 Apr 20. p. 198-9. New Drug Application No.: 20-797.
36. 36. Advisory Committee for Reproductive Health Drugs. Pooled analysis of the CAP-001 studies. Bethesda (MD): Center for Drug Evaluation and Research, Food and Drug Administration; 1998 Apr 20. New Drug Application No.: 20-797.
37. 37. Advisory Committee for Reproductive Health Drugs. Bethesda (MD): Center for Drug Evaluation and Research, Food and Drug Administration; 1998 Apr 20. p. 24. New Drug Application No.: 20-797.
38. 38. Creasy RK, Katz M. Basic research and clinical experiences with β-adrenergic tocolytics in the United States. In: Fuchs A-R, Fuchs F, Stubblefield PG, editors. Preterm birth: causes, prevention, and management. 2nd ed. New York: McGraw-Hill; 1993. p. 243-77.
39. 39. Moutquin J-M, Sherman D, Cohen H, Mohide PT, Hochner-Celnikier D, Fejgin M, et al. Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study. Am J Obstet Gynecol 2000;182:1191-9.
40. 40. Advisory Committee for Reproductive Health Drugs. Bethesda (MD): Center for Drug Evaluation and Research, Food and Drug Administration; 1998 Apr 20. p. 60. New Drug Application No.: 20-797.
41. 41. Shankaran S, Papile LA, Wright LL, Ehrenkranz RA, Mele L, Lemons JA, et al. The effect of antenatal phenobarbital therapy on neonatal intracranial hemorrhage in preterm infants. N Engl J Med 1997;337:466-71.
42. 42. Mittendorf R, Covert R, Bowman J, Khoshnood B, Lee KS, Siegler M. Is tocolytic magnesium sulphate associated with increased total paediatric mortality? Lancet 1997;350:1517-8.
43. 43. Mittendorf R, Pryde P, Khoshnood B, Lee KS. If tocolytic magnesium sulfate is associated with excess total pediatric mortality, what is its impact? Obstet Gynecol 1998;92:308-11.
44. 44. The Eclampsia Trial Collaborative Group. Which anticonvulsant for women with eclampsia? Evidence from the Collaborative Eclampsia Trial. Lancet 1995;345:1455-63.